One in three (31%) Finnish men suffering from erectile dysfunction have not sought any kind of help or treatment for their condition. Navamedic, a nordic pharma company, introduced to the Finnish market the first non-prescription topical treatment for erectile dysfunction, Eroxon. Our goal was to accelerate Eroxon’s commercial success and to drive a cultural shift in public discussion: men’s sexual health must be talked about.
